Status unknownNCT03364920Updated Dec 7, 2017

Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis

An observational study in Pancreatitis, Acute, sponsored by Weiqin Li. Status unknown. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-07.

Sponsored by Weiqin Li · Observational

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Study type: Observational
Model: Cohort
Time perspective: Retrospective
Enrollment: 200
Ages: 18 Years to 75 Years
Sex: All

Study summary

This is a retrospective study about serum Maresin-1 level in different severe acute pancreatitis patients. The investigators want to study the correlation between the level of serum Maresin-1 and the severity of SAP, of course the clinical outcomes. The investigators want to find some biomarkers and strategy target drugs of severe acute pancreatitis.

Conditions studied

Pancreatitis, Acute

Browse trials for

Pancreatitis 751

Keywords

Maresin-1
SAP
IPN
MODS
Mortality

Who can participate

Ages eligible: 18 Years to 75 Years
Sexes eligible: All
Accepts healthy volunteers: Yes
Sampling method: Non-probability sample

Study population

This study includes severe acute pancreatitis between 18ys and 75ys.Patients with disorder of glucolipide metabolism will be excluded. Alcoholic pancreatitis and HTG-AP patients will be also excluded. Patients will be divided into 2 groups according to their level of serum maresin-1.

Inclusion criteria

Clinical diagnosis of Severe Acute Pancreatitis
Biliary pancreatitis
7 days of the onset

Exclusion criteria

Exclusion Criteria:

Surgical patients
Serious diseases and infection
Alcoholic pancreatitis
Hypertriglyceridemia pancreatitis
Disorder of Glucolipide Metabolism：diabetes mellitus, hypertriglyceridemia, BMI>30

Study design

Observational model: Cohort
Time perspective: Retrospective
Enrollment: 200 participants (estimated)
Patient registry: No

Groups and cohorts

normal level of serum maresin-1
abnormal level of serum maresin-1

What researchers measure

Primary outcomes

mortality
The level of serum maresin-1 predicts the severity of severe acute pancreatitis
Time frame: up to 28 days

Secondary outcomes

The incidence of MODS
The level of serum maresin-1 predicts the severity of severe acute pancreatitis
Time frame: through study completion, an average of 1 year
The incidence of IPN
The level of serum maresin-1 predicts the severity of severe acute pancreatitis
Time frame: through study completion, an average of 1 year

Study locations

No study locations are listed for this record.

Registry details

Key details

Study ID: NCT03364920
Lead sponsor: Weiqin Li
Responsible party: Weiqin Li (Doctor, Nanjing University School of Medicine) — Sponsor-investigator
First posted: Dec 7, 2017
Start date: Jan 1, 2018 (estimated)
Primary completion: Jan 1, 2019 (estimated)
Completion: Jan 1, 2020 (estimated)
Last update: Dec 7, 2017

Study contacts

Weiqin Li

Contact

luyingying126@sina.cn

13962531994

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pancreatitis→

Other studies from this sponsor